San Francisco, CA. February 20, 2022 — The Vial Dermatology CRO announced the addition of Mark Lebwohl, MD, MPH to the Vial Scientific Advisory Board. Dr. Lebwohl will lend his expertise to the Vial CRO team and leading sponsors working to advance the Dermatology research field.
Launched earlier this year, under the tag line, “The CRO Built for Sponsors”, the Vial Dermatology CRO promises higher quality and faster execution of trials powered by the Vial Clinic Network of over 35 Dermatology clinics across the country. The Vial Scientific Advisory Board’s leading Dermatology KOLs will service sponsors in clinical strategy, regulatory strategy, trial design and indication selection.
The Vial Dermatology CRO team is led by Betsey Zbyszynski as Head of Clinical Operations, Jason Shuris as Head of Sales, Janet DuBois, M.D. as Medical Director, Justin Withers as Head of Dermatology. The CRO executive team joins Vial with over 100+ years of combined dermatology clinical trial experience.
Dr. Lebwohl stated: “The development of a technology-centric CRO that can drive much-needed progress in Dermatology research is exciting, and I’m delighted to join their Scientific Advisory Board.”
Dr. Mark Lebwohl graduated summa cum laude from Columbia College in 1974 and graduated from Harvard Medical School in 1978. He completed residencies at Mount Sinai in both internal medicine and dermatology. Dr. Lebwohl has served as president of the New York Dermatological Society, the Manhattan Dermatologic Society, and the New York State Society of Dermatology, and as chairman of the Dermatology Section of the New York Academy of Medicine. Dr. Lebwohl is a past chairman of the Psoriasis Task Force of the American Academy of Dermatology, and has directed the AAD’s annual Psoriasis Symposium, Diagnostic Update Symposium and Therapeutics Symposium as well as the Academy’s annual meeting and summer meeting. In 2015-16 he served as President of the American Academy of Dermatology.
Dr. Lebwohl is chairman emeritus of the Medical Board of the National Psoriasis Foundation. He is the founding editor of Psoriasis Forum and the Journal of Psoriasis and Psoriatic Arthritis. He has been on the editorial board of the Journal of the American Academy of Dermatology and the Journal of Skin Cancer. He is editor of the Dermatology Section of Scientific American Medicine and co-Editor-in-Chief of Skin, the Journal of Cutaneous Medicine. He has authored or co-authored over 600 publications including articles, chapters and abstracts. Dr. Lebwohl is actively involved in clinical trials of many new dermatologic treatments.
Vial’s mission is to run clinical trials with faster execution and higher quality in order to bring new therapies to market. Vial has over 70 employees and is based in San Francisco, California. Vial partners with Dermatologists to support their research teams and has created a network of over 35 Dermatology clinics. The Vial network has contributed to over 150 trials for many of the leading sponsors in Dermatology having run trials across common Medical Dermatology indications (Atopic Dermatitis, Psoriasis, Vitiligo, Alopecia Areata, Rosacea, Hidradenitis Suppurativa, Prurigo Nodularis among others) as well as Aesthetic Dermatology indications. The clinic network runs trials from Phase I through Phase IV.